These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12493444)

  • 1. Donor cardiac allografts from p53 knockout mice exhibit apoptosis-independent prolongation of survival.
    Kown MH; Murata S; Jahncke CL; Mari C; Berry GJ; Lijkwan MA; Blankenberg FG; Strauss HW; Robbins RC
    Transplant Proc; 2002 Dec; 34(8):3274-6. PubMed ID: 12493444
    [No Abstract]   [Full Text] [Related]  

  • 2. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling.
    Orosz CG; Huang EH; Bergese SD; Sedmak DD; Birmingham DJ; Ohye RG; VanBuskirk AM
    J Heart Lung Transplant; 1997 Sep; 16(9):889-904. PubMed ID: 9322138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated acute cardiac rejection in NOS2 -/- recipients correlates with reduced apoptosis.
    Koglin J; Granville DJ; Glysing-Jensen T; Mudgett JS; Carthy CM; McManus BM; Russell ME
    Circulation; 1999 Feb; 99(6):836-42. PubMed ID: 9989972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged survival of heart allografts from p53-deficient mice.
    Hu Y; Zou Y; Hala M; Dietrich H; Wick G; Xu Q
    Transplantation; 2000 Jun; 69(12):2634-40. PubMed ID: 10910287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
    Djamali A; Odorico JS
    Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection.
    Haskova Z; Izawa A; Contreras AG; Flynn E; Boulday G; Briscoe DM
    Transplantation; 2007 Jun; 83(12):1595-601. PubMed ID: 17589343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous allograft tolerance in B7-deficient mice independent of preexisting endogenous CD4+CD25+ regulatory T-cells.
    Grazia TJ; Plenter RJ; Doan AN; Kelly BP; Weber SM; Kurche JS; Cushing SO; Gill RG; Pietra BA
    Transplantation; 2007 Jun; 83(11):1449-58. PubMed ID: 17565318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting.
    Wang H; Hosiawa KA; Min W; Yang J; Zhang X; Garcia B; Ichim TE; Zhou D; Lian D; Kelvin DJ; Zhong R
    J Immunol; 2003 Oct; 171(7):3823-36. PubMed ID: 14500684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged allograft survival in TNF receptor 1-deficient recipients is due to immunoregulatory effects, not to inhibition of direct antigraft cytotoxicity.
    McKee CM; Defina R; He H; Haley KJ; Stone JR; Perkins DL
    J Immunol; 2002 Jan; 168(1):483-9. PubMed ID: 11751996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR4-deficient mice show prolonged graft survival in a chronic cardiac transplant rejection model.
    Hüser N; Tertilt C; Gerauer K; Maier S; Traeger T; Assfalg V; Reiter R; Heidecke CD; Pfeffer K
    Eur J Immunol; 2005 Jan; 35(1):128-38. PubMed ID: 15593118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pillars article: long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996. 381: 434-438. 1996.
    Larsen CP; Elwood ET; Alexander DZ; Ritchie SC; Hendrix R; Tucker-Burden C; Cho HR; Aruffo A; Hollenbaugh D; Linsley PS; Winn KJ; Pearson TC
    J Immunol; 2011 Mar; 186(5):2693-7. PubMed ID: 21325218
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction of tolerance to cardiac allografts by pretreatment with intrathymic UVB donor spleen cells.
    Oluwole SF; Chowdhury N; Fawwaz R; Hardy MA
    Transplant Proc; 1992 Dec; 24(6):2904-5. PubMed ID: 1465993
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
    Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
    Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor antioxidant strategy prolongs cardiac allograft survival by attenuating tissue dendritic cell immunogenicity(†).
    Jurewicz M; Ueno T; Azzi J; Tanaka K; Murayama T; Yang S; Sayegh MH; Niimi M; Abdi R
    Am J Transplant; 2011 Feb; 11(2):348-55. PubMed ID: 21182586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of anergic cells' adoptive transfer and rapamycin therapy prolongs cardiac allograft survival in mice.
    Cai Y; Tang XD; Zhou PJ
    Scand J Immunol; 2005 Mar; 61(3):266-73. PubMed ID: 15787744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor-derived IP-10 initiates development of acute allograft rejection.
    Hancock WW; Gao W; Csizmadia V; Faia KL; Shemmeri N; Luster AD
    J Exp Med; 2001 Apr; 193(8):975-80. PubMed ID: 11304558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor microchimerism is not responsible for the maintenance of tolerance to donor alloantigens in recipients tolerant of cardiac allografts.
    Hamano K; Rawsthorne M; Bushell A; Morris PJ; Wood KJ
    Transplant Proc; 1995 Feb; 27(1):151-2. PubMed ID: 7878951
    [No Abstract]   [Full Text] [Related]  

  • 19. Survival of MHC deficient mouse heterotopic cardiac allografts and xenografts.
    Campos L; Deli BC; Kern JH; Kim JI; Naji A; Barker CF; Markmann JF
    Transplant Proc; 1995 Feb; 27(1):254-5. PubMed ID: 7878991
    [No Abstract]   [Full Text] [Related]  

  • 20. Heart, but not skin, allografts from donors lacking Flt3 ligand exhibit markedly prolonged survival time.
    Wang Z; Castellaneta A; De Creus A; Shufesky WJ; Morelli AE; Thomson AW
    J Immunol; 2004 May; 172(10):5924-30. PubMed ID: 15128773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.